+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

Bradykinin Receptor B1 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Bradykinin Receptor B1 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Bradykinin Receptor B2 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Bradykinin Receptor B2 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
CRF1 Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

CRF1 Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
C5a Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

C5a Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
CXCR4 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

CXCR4 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Alpha 4 Beta 7 (A4b7) Integrin Inhibitor- - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha 4 Beta 7 (A4b7) Integrin Inhibitor- - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Glucocorticoid induced tumor necrosis factor - Pipeline Insight, 2024 - Product Thumbnail Image

Glucocorticoid induced tumor necrosis factor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Selectin Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Selectin Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Broad Spectrum Chemokine Inhibitor (BSCIs) - Pipeline Insight, 2024 - Product Thumbnail Image

Broad Spectrum Chemokine Inhibitor (BSCIs) - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Bradykinin Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Bradykinin Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Kallikrein Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Kallikrein Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Interleukin-2 (IL-2) Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-2 (IL-2) Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Glucocorticoid receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Glucocorticoid receptor antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Interleukin-10 (IL-10) Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-10 (IL-10) Receptor Agonist - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Interleukin-12 (IL-12) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-12 (IL-12) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Interleukin-17 (IL-17) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-17 (IL-17) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Interleukin-23 (IL-23) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-23 (IL-23) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 90 Pages
  • Global
From
Interleukin-5 (IL-5) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-5 (IL-5) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Interleukin-8 (IL-8) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-8 (IL-8) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Toll-like receptor 4 antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Toll-like receptor 4 antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more